Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1383&sort=-abstract
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-abstract", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=-abstract", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1384&sort=-abstract", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1382&sort=-abstract" }, "data": [ { "type": "Grant", "id": "8981", "attributes": { "award_id": "5R01MD016026-02", "title": "Reducing Racial Disparities in SMM post COVID19: Assessing the integration of maternal safety bundles and community based doulas to improve outcomes for Black women", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6437, "first_name": "Rada K", "last_name": "Dagher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-17", "end_date": "2025-06-30", "award_amount": 630060, "principal_investigator": { "id": 23456, "first_name": "NDIDIAMAKA", "last_name": "AMUTAH-ONUKAGHA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 863, "ror": "", "name": "TUFTS UNIVERSITY BOSTON", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22627, "first_name": "Hafsatou", "last_name": "Diop", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1517, "ror": "", "name": "MASSACHUSETTS STATE DEPT OF PUB HEALTH", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, { "id": 23457, "first_name": "EUGENE R", "last_name": "DECLERCQ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 863, "ror": "", "name": "TUFTS UNIVERSITY BOSTON", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "(Project Summary) Black women experience stark disparities in pregnancy care, complications, and outcomes, compared to White women. Recognizing, tracking and understanding patterns of severe maternal mortality (SMM) and associated inequities by race/ethnicity, along with developing and carrying out interventions to improve the quality of maternal care, are essential to reducing SMM and thereby maternal mortality. To date, there has been little research specifically aimed at understanding whether the maternal health inequities as experienced by Black women can be ameliorated through an integrated care model that includes engagement of mothers of color in the planning and implementation of maternal safety bundles in addition to prenatal, birth and postpartum support from community doulas. We intend to use the Health Impact Pyramid to develop, implement and assess the effectiveness of such a system in reducing disparities in SMM and mortality. The data sources for this study will include state-level and hospital-specific discharge data collected as part of the Alliance for Innovation on Maternal Health (AIM) project; the Maternal Mortality Review Committee (MMRC); and the Pregnancy to Early Life Longitudinal (PELL) data system, which focuses on population-level data needed to examine health inequities among racial and ethnic minorities in Massachusetts. In addition to these existing data sources, we intend to establish a data collection tool to assess doula services as well as analyze qualitative data from interviews with black women, and focus groups with providers and doulas to explore the effect of incorporating doula-provided services into prenatal, birth and postpartum care. This proposal has three main study areas that will lead to a systematic understanding of ways to address and prevent SMM among black women and thus, establish a foundation for the development, testing and scale-up of future interventions to improve maternal health outcomes: 1) Use longitudinally linked hospital discharge data from PELL (2008-2018) to characterize preconception, prenatal and postpartum hospital encounters among women with SMM in order to identify key points where opportunities to intervene were missed. 2): Among hospitals that serve black women, to assess the impact of implementing maternal safety bundles to ensure that black women are receiving quality obstetric care 3): Examine how systems integrating community-based doula support could decrease the inequities of SMM among black and white mothers. Our study will lead to a more systematic understanding of pregnancy outcomes for Black women at highest risk of SMM, thus establishing a foundation for development and testing of future interventions to improve maternal outcomes.", "keywords": [ "Address", "Area", "Attitude", "Biological", "Birth", "COVID-19", "Caring", "Centers for Disease Control and Prevention (U.S.)", "Color", "Communities", "Data", "Data Collection", "Data Linkages", "Data Sources", "Development", "Discipline of obstetrics", "Ensure", "Ethnic Origin", "Ethnic group", "Focus Groups", "Foundations", "Future", "Health", "Health Personnel", "Hemorrhage", "High Prevalence", "High Risk Woman", "Hispanics", "Hospitalization", "Hospitals", "Hypertension", "Individual", "Information Systems", "Intervention", "Interview", "Investigation", "Life", "Link", "Live Birth", "Massachusetts", "Maternal Health", "Maternal Mortality", "Medical Care Team", "Methods", "Modeling", "Morbidity - disease rate", "Mothers", "Not Hispanic or Latino", "Outcome", "Pattern", "Perinatal Care", "Population", "Postpartum Period", "Pregnancy", "Pregnancy Complications", "Pregnancy Outcome", "Prenatal care", "Provider", "Public Health", "Race", "Recommendation", "Reporting", "Research", "Review Committee", "Risk", "Services", "System", "Testing", "Time", "United States", "Woman", "Women&apos", "s Group", "Women&apos", "s Health", "base", "black women", "design", "disparity reduction", "effectiveness evaluation", "ethnic minority population", "experience", "health care service utilization", "health disparity", "health inequalities", "hybrid type 1 trial", "implementation framework", "implementation outcomes", "implementation process", "implementation science", "improved", "improved outcome", "innovation", "longitudinal design", "maternal outcome", "maternal safety", "mortality", "mortality disparity", "obstetric care", "peer", "postpartum care", "prenatal", "prevent", "preventable death", "programs", "racial disparity", "racial minority", "scale up", "secondary analysis", "severe maternal morbidity", "tool" ], "approved": true } }, { "type": "Grant", "id": "9677", "attributes": { "award_id": "1P30ES032756-01A1", "title": "Pilot Project Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-06-24", "end_date": "2026-03-31", "award_amount": 378860, "principal_investigator": { "id": 25498, "first_name": "Thomas", "last_name": "Hartung", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "(PILOT PROJECT PROGRAM) The Pilot Project Program (PPP) is critical to the ability of the Center for Community Health: Addressing Regional Maryland Environmental Determinants of Disease (CHARMED) to achieve its central goals of fostering innovative interdisciplinary research in environmental health, translating knowledge into action to address community environmental challenges in the Maryland region, and nurturing and supporting the next generation of environmental scientists. Funding pilot grants represents a major strategy for promoting and supporting community-scientist partnerships, seeding emerging research areas, driving development of novel scientific approaches, and supporting translational research in environmental health research that could evolve into independently funded research. The Specific Aims of the PPP are to: 1) To foster and support research that addresses environmental health challenges of communities in the Maryland region; 2) facilitate the dissemination of findings from CHARMED-supported Pilot Projects to relevant stakeholders; and 3) evaluate the effectiveness and impact of the PPP. To achieve these goals, the PPP will provide pilot project funding for four types of research proposals: 1) Community-Engaged Research (CEnR) Awards, which will be awarded to any JHU or university faculty in the Maryland region working together with community partners on projects designed and conducted with the active participation of said partners; 2) Career Development Awards (CD), which will promote and support the success of the careers of Early Stage and Mid-career Investigators in community- engaged environmental health research; 3) New Direction Awards (ND), which will support high impact, innovative projects that focus on the scientific themes of the Center, especially those which lead to the pursuit of multi-investigator grants; which will be awarded to established investigators from non-environmental health disciplines who intend to expand their research to include environmental health research; 4) Rapid Response Pilot Project Awards (RRP), which will enable investigators to address emergent environmental concerns (e.g. hurricanes, COVID-19, oil spills) and or to generate preliminary data for grant submissions or resubmissions to enhance their chances of success. Applications will receive high priority if they address important community concerns, are likely to lead to extramural funding, utilize one or more facility cores, and or bring innovative approaches to the field. As all pilot project grant awardees will be expected to become Center members and participate in all Center activities, we anticipate that this funding mechanism will greatly expand the community- engaged research activities of the Center by fostering an ecosystem of innovative research in environmental health focused on the main scientific themes of the Center.", "keywords": [ "Address", "Area", "Automobile Driving", "Award", "COVID-19", "Communities", "Community Health", "Core Facility", "Data", "Decision Making", "Development", "Discipline", "Disease", "Ecosystem", "Environmental Exposure", "Environmental Health", "Extramural Activities", "Faculty", "Faculty Recruitment", "Fostering", "Funding", "Funding Mechanisms", "Goals", "Grant", "Group Meetings", "Historically Black Colleges and Universities", "Hurricane", "Incentives", "Institution", "Interdisciplinary Study", "K-Series Research Career Programs", "Knowledge", "Lead", "Maryland", "Mentorship", "Neighborhood Health Center", "Oils", "Outcome", "Peer Review", "Pennsylvania", "Pilot Projects", "Press Releases", "Public Health", "Publications", "Research", "Research Activity", "Research Personnel", "Research Proposals", "Research Support", "Resources", "Risk", "Science", "Scientist", "Seeds", "Services", "Time", "Translating", "Translational Research", "Translations", "Universities", "base", "career", "community center", "community engaged research", "dashboard", "design", "effectiveness evaluation", "environmental justice", "faculty community", "high risk", "improved", "innovation", "meetings", "member", "mid-career faculty", "new technology", "next generation", "novel", "prevent", "programs", "response", "social media", "success", "symposium", "web site" ], "approved": true } }, { "type": "Grant", "id": "11234", "attributes": { "award_id": "5P30ES032756-02", "title": "Pilot Project Program", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Environmental Health Sciences (NIEHS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-06-24", "end_date": "2026-03-31", "award_amount": 378860, "principal_investigator": { "id": 25498, "first_name": "Thomas", "last_name": "Hartung", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "(PILOT PROJECT PROGRAM) The Pilot Project Program (PPP) is critical to the ability of the Center for Community Health: Addressing Regional Maryland Environmental Determinants of Disease (CHARMED) to achieve its central goals of fostering innovative interdisciplinary research in environmental health, translating knowledge into action to address community environmental challenges in the Maryland region, and nurturing and supporting the next generation of environmental scientists. Funding pilot grants represents a major strategy for promoting and supporting community-scientist partnerships, seeding emerging research areas, driving development of novel scientific approaches, and supporting translational research in environmental health research that could evolve into independently funded research. The Specific Aims of the PPP are to: 1) To foster and support research that addresses environmental health challenges of communities in the Maryland region; 2) facilitate the dissemination of findings from CHARMED-supported Pilot Projects to relevant stakeholders; and 3) evaluate the effectiveness and impact of the PPP. To achieve these goals, the PPP will provide pilot project funding for four types of research proposals: 1) Community-Engaged Research (CEnR) Awards, which will be awarded to any JHU or university faculty in the Maryland region working together with community partners on projects designed and conducted with the active participation of said partners; 2) Career Development Awards (CD), which will promote and support the success of the careers of Early Stage and Mid-career Investigators in community- engaged environmental health research; 3) New Direction Awards (ND), which will support high impact, innovative projects that focus on the scientific themes of the Center, especially those which lead to the pursuit of multi-investigator grants; which will be awarded to established investigators from non-environmental health disciplines who intend to expand their research to include environmental health research; 4) Rapid Response Pilot Project Awards (RRP), which will enable investigators to address emergent environmental concerns (e.g. hurricanes, COVID-19, oil spills) and or to generate preliminary data for grant submissions or resubmissions to enhance their chances of success. Applications will receive high priority if they address important community concerns, are likely to lead to extramural funding, utilize one or more facility cores, and or bring innovative approaches to the field. As all pilot project grant awardees will be expected to become Center members and participate in all Center activities, we anticipate that this funding mechanism will greatly expand the community- engaged research activities of the Center by fostering an ecosystem of innovative research in environmental health focused on the main scientific themes of the Center.", "keywords": [ "Address", "Area", "Automobile Driving", "Award", "COVID-19", "Communication", "Communities", "Core Facility", "Data", "Decision Making", "Development", "Discipline", "Disease", "Ecosystem", "Environmental Exposure", "Environmental Health", "Extramural Activities", "Faculty", "Faculty Recruitment", "Fostering", "Funding", "Funding Mechanisms", "Goals", "Grant", "Group Meetings", "Health", "Historically Black Colleges and Universities", "Hurricane", "Incentives", "Interdisciplinary Study", "K-Series Research Career Programs", "Knowledge", "Lead", "Maryland", "Mentorship", "Neighborhood Health Center", "Oils", "Outcome", "Peer Review", "Pennsylvania", "Pilot Projects", "Press Releases", "Public Health", "Publications", "Research", "Research Activity", "Research Institute", "Research Personnel", "Research Proposals", "Research Support", "Resources", "Risk Reduction", "Science", "Scientist", "Services", "Time", "Translating", "Translational Research", "Translations", "Universities", "career", "community center", "community engaged research", "dashboard", "design", "effectiveness evaluation", "environmental justice", "high risk", "improved", "innovation", "meetings", "member", "mid-career faculty", "new technology", "next generation", "novel", "prevent", "programs", "response", "social media", "success", "symposium", "web site" ], "approved": true } }, { "type": "Grant", "id": "12206", "attributes": { "award_id": "1UC7AI180309-01", "title": "UofL RBL Operations, Workforce Development and Pandemic Preparedness Research", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27982, "first_name": "FAYNA C", "last_name": "Diaz San Segundo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-18", "end_date": "2028-07-31", "award_amount": 2935664, "principal_investigator": { "id": 28078, "first_name": "KENNETH E", "last_name": "PALMER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 795, "ror": "https://ror.org/01ckdn478", "name": "University of Louisville", "address": "", "city": "", "state": "KY", "zip": "", "country": "United States", "approved": true }, "abstract": "(OVERALL): The University of Louisville Regional Biocontainment Laboratory (RBL) is operated by the University Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM). The RBL is a regional resource that facilitates translational research to develop diagnostics, prognostics, therapeutics and vaccines to mitigate biodefense and emerging infectious disease threats. Our Center operates the only BSL-3 and ABSL-3 facilities currently operating in the Commonwealth of Kentucky. The CPM mandate is to prepare for and respond to public health emergencies, such as the COVID-19 pandemic. The broad, long-range objectives and goals of the University of Louisville (UofL) CPM RBL are: 1. To offer state-of-the-art research services to the regional and national biomedical research community to learn from past pandemics and biological warfare experiences and effectively predict and mitigate future emerging infectious disease threats. 2. To manage, maintain and operate the UofL RBL to serve the national and regional need for biocontainment facilities suitable for research on Risk Group 3 pathogens and other biothreats. 3. To follow a philosophy of continuous improvement in BSL-3 and ABSL-3 work practices and to ensure that all personnel who need to access BSL-3 and ABSL-3 containment laboratories are appropriately trained and prepared to serve the national and regional need for biocontainment research professionals. To achieve these aims we propose to establish three collaborative Cores. The Facilities Management Maintenance and Operations Core (FMMO Core) is responsible for ensuring that the facility is always available to meet the research and emergency preparedness mission of the RBL. The BSL-3 Practices and Workforce Development Core (BSL-3PWD Core) formalizes our mentor-mentee training plan to ensure our laboratory is staffed with BSL-3 research professionals who are proficient at biocontainment research professionals. This core responds to the reality that response to rapidly emerging public health emergencies like COVID-19 is limited by the number of available BSL-3 trained and experienced research professionals. Our Pandemic Preparedness and Response Integrated Research Core (PaPR Core) responds to the substantially increased requests for our BSL-3 research services by organizing an integrated full-service BSL-3 research support function to support investigator needs. These cores will work in unison to achieve the CPM mission: to prepare for and respond to public health emergencies like the COVID-19 pandemic.", "keywords": [ "Attention", "Biological Warfare", "Biomedical Research", "Biotechnology", "COVID-19", "COVID-19 pandemic", "COVID-19 patient", "China", "Clinical Trials", "Communities", "Containment", "Creativeness", "Crowns", "Dedications", "Diagnostic", "Disease Outbreaks", "Economics", "Emerging Communicable Diseases", "Ensure", "Federal Government", "Funding Opportunities", "Future", "Goals", "Health Services Research", "Health care facility", "Hospitals", "Hour", "Human Resources", "Industry", "Infection", "Institution", "International", "Investigational New Drug Application", "Kentucky", "Laboratories", "Leadership", "Learning", "Maintenance", "Managed Care", "Medicine", "Mentors", "Mission", "Modeling", "National Center for Advancing Translational Sciences", "National Institute of Diabetes and Digestive and Kidney Diseases", "Nose", "Patients", "Philosophy", "Play", "Public Health", "Research", "Research Personnel", "Research Support", "Resources", "Rest", "Reverse Transcriptase Polymerase Chain Reaction", "Risk", "Role", "Scientist", "Serology test", "Services", "System", "Talents", "Techniques", "Testing", "Therapeutic", "Training", "Translational Research", "United States National Institutes of Health", "Universities", "University resources", "Vaccines", "Work", "Workforce Development", "biocontainment facility", "biodefense", "biothreat", "cohort", "experience", "improved", "laboratory experience", "medical countermeasure", "metropolitan", "novel", "novel coronavirus", "operation", "pandemic disease", "pandemic preparedness", "pandemic response", "pathogen", "previous pandemic", "prognostic", "prophylactic", "public health emergency", "recruit", "response", "service organization", "skills", "wastewater surveillance" ], "approved": true } }, { "type": "Grant", "id": "9766", "attributes": { "award_id": "1P50CA271338-01", "title": "Advancing cancer care and equity through telehealth, communication science, and behavioral economics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Cancer Institute (NCI)" ], "program_reference_codes": [], "program_officials": [ { "id": 25610, "first_name": "ROBIN CLINE", "last_name": "Vanderpool", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-01", "end_date": "2027-07-31", "award_amount": 1137500, "principal_investigator": { "id": 25611, "first_name": "Justin", "last_name": "Bekelman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 25612, "first_name": "Katharine", "last_name": "Rendle", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 25613, "first_name": "ANIL", "last_name": "VACHANI", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "(OVERALL) The University of Pennsylvania Telehealth Research Center in Cancer Care (Penn TRC) will apply insights from communication science and behavioral economics to design and test innovative telehealth strategies to improve effectiveness and equity across the cancer care continuum, with an emphasis on understanding mechanisms of action. The COVID-19 pandemic led to dramatic growth in the use of telehealth for cancer care delivery, fostered by both clinical need and temporary waivers. Telehealth strategies have included both synchronous communication (real-time video or telephone conferencing) and asynchronous communication (sequential health information exchange through text messaging or secure portals). Yet, fundamental knowledge gaps include the extent to which telehealth may be superior to non-telehealth care delivery strategies for access, quality, and outcomes; how telehealth may enhance or detract from achieving health equity in cancer care in the context of the digital divide and persistent cancer disparities; and the impact of telehealth on health care efficiency. The Penn TRC will address an overarching research theme: to apply insights from communication science and behavioral economics to design and test synchronous telehealth strategies, supported by asynchronous elements, to improve access, quality, outcomes, equity, and efficiency across the cancer care continuum. We focus on lung cancer as a model for telehealth across the care continuum, from screening to treatment to survivorship. We bring together a team of international experts in communication science, behavioral economics, cancer care delivery, telehealth, health care innovation, mixed methods, and health equity to achieve the following specific aims: 1) Apply concepts, strategies, tools, and methods from communication science and behavioral economics to design and test synchronous telehealth strategies, supported by asynchronous elements, to improve access, quality, outcomes, equity, and efficiency for patients across the care continuum; 2) Conduct a pragmatic randomized clinical trial to compare the effectiveness of telehealth strategies to increase shared decision making for lung cancer screening using a Sequential Multiple Assignment Randomized Trial (SMART) design; 3) Conduct two rapid-cycle pilot projects, with methods and measures aligned with the pragmatic trial, to design and test the effectiveness of telehealth to improve cancer care, identify multilevel mechanisms of action, and lay the foundation for future, more definitive pragmatic trials; and 4) Build capacity to advance a national telehealth research agenda and train the next generation of investigators with expertise in cancer care, telehealth and health equity. By joining together interdisciplinary faculty across Penn, the Penn TRC will result in novel, scalable, and generalizable disseminated strategies to drive lasting improvements in cancer care and health equity. Penn has an unparalleled environment in which to bring together these areas of study.", "keywords": [ "Address", "Advanced Malignant Neoplasm", "American", "Area", "Award", "COVID-19 pandemic", "Clinical", "Communication", "Communication Methods", "Continuity of Patient Care", "Discipline", "Doctor of Philosophy", "Effectiveness", "Elements", "Environment", "Faculty", "FarGo", "Fostering", "Foundations", "Future", "Goals", "Grant", "Growth", "Health", "Health Services Accessibility", "Healthcare", "Improve Access", "Individual", "International", "Intervention", "Knowledge", "Learning", "Malignant neoplasm of lung", "Measures", "Methods", "Mind", "Modeling", "Molecular", "Nurses", "Outcome", "Palliative Care", "Patients", "Pennsylvania", "Pilot Projects", "Randomized Clinical Trials", "Recommendation", "Research", "Research Methodology", "Research Personnel", "Resources", "Science", "Secure", "Sequential Multiple Assignment Randomized Trial", "Telephone", "Testing", "Text Messaging", "Time", "Training", "Universities", "Work", "asynchronous communication", "behavioral economics", "cancer care", "cancer health disparity", "care delivery", "clinical practice", "compare effectiveness", "design", "digital", "effectiveness testing", "evidence base", "health equity", "improved", "innovation", "insight", "lung cancer screening", "next generation", "novel", "pragmatic trial", "screening", "shared decision making", "survivorship", "symposium", "telehealth", "tool", "trial design", "waiver" ], "approved": true } }, { "type": "Grant", "id": "7374", "attributes": { "award_id": "3U42OD011140-18S1", "title": "National Swine Resource and Research Center 1", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 20741, "first_name": "MIGUEL A.", "last_name": "CONTRERAS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2003-09-01", "end_date": "2023-07-31", "award_amount": 499943, "principal_investigator": { "id": 23167, "first_name": "RANDALL S", "last_name": "PRATHER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23168, "first_name": "Kevin Dale", "last_name": "Wells", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1049, "ror": "", "name": "UNIVERSITY OF MISSOURI-COLUMBIA", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "(Overall) The overall goal of this application is to continue and expand operation of the National Swine Resource and Research Center (NSRRC). The NSRRC is in its 14th year of operation and it has developed the infrastructure needed to assist swine-based research across multiple disciplines, including xenotransplantation. The NSRRC has developed new models of human disease by genetic engineering, it has recruited models created by others, and it has distributed expertise, cells, tissues, organs and pigs to investigators throughout the United States. Since genetic engineering of pigs requires specialized facilities and expertise, the NSRRC provides invaluable services to the research community by using the latest in gene editing technology to create new genetically-engineered swine models. The NSRRC also provides training and education by interacting with individuals, publishing manuscripts and sponsoring workshops and meetings that promote the use of pigs for studying human diseases. The NSRRC has a state-of-the-art building with high biosecurity to house animals free of specific pathogens. The Specific Aims for the upcoming grant period are as follows: 1. To operate the National Swine Research and Resource Center. Functions of the NSRRC will continue to include: a) importation of existing swine models of human health and disease; b) rederivation of pigs to eliminate specific pathogens, and health monitoring to assure maintenance of a specific pathogen-free status; c) cryopreservation and storage of gametes, embryos, and somatic cells to prevent future loss of valuable models; d) distribution of expertise, reagents, cells, tissues, organs, and pathogen-free pigs; and e) use state of the art technology for the creation of new genetically-engineered pigs needed by the biomedical research community. Rigorous quality control will ensure that only high quality genetics are distributed. The NSRRC will also serve as a site for training and educational activities related to research employing swine models. 2. To perform innovative research that will benefit the NSRRC and the biomedical research community. Applied research projects are aimed at improving: a) the cryopreservation of pig reproductive cells and tissues, b) methods for the production of genetically-engineered pigs, c) state-of-the-art testing methods for swine health surveillance, and d) right-size the pig for greater adoption of pig models.", "keywords": [ "Adoption", "Anatomy", "Animals", "Applied Research", "Area", "Arteriosclerosis", "Biomedical Research", "Cardiovascular Diseases", "Cells", "Characteristics", "Communicable Diseases", "Communities", "Country", "Critical Pathways", "Cryopreservation", "Diabetes Mellitus", "Discipline", "Disease", "Educational Activities", "Educational workshop", "Embryo", "Ensure", "Family suidae", "Future", "Genes", "Genetic", "Genetic Diseases", "Genetic Engineering", "Genetic Materials", "Germ Cells", "Goals", "Grant", "Health", "Human", "Individual", "Infrastructure", "Laboratories", "Maintenance", "Manuscripts", "Medical Device", "Medical Research", "Methods", "Modeling", "Modification", "Molecular", "Monitor", "Optics", "Organ", "Patients", "Pharmaceutical Preparations", "Physiological", "Physiology", "Play", "Production", "Progress Reports", "Publishing", "Quality Control", "Reagent", "Reproducibility", "Research", "Research Personnel", "Research Project Grants", "Resources", "Role", "Scientist", "Serologic tests", "Services", "Site", "Somatic Cell", "Study models", "Technology", "Testing", "Therapeutic", "Therapeutic Agents", "Tissues", "Training Activity", "Training and Education", "Translational Research", "United States", "United States National Institutes of Health", "Xenograft procedure", "animal care", "base", "biosecurity", "clinical practice", "drug development", "embryo cell", "experience", "germ free condition", "human disease", "human model", "improved", "innovation", "investigator training", "meetings", "novel therapeutic intervention", "novel therapeutics", "operation", "pathogen", "pig genome", "pre-clinical", "predictive modeling", "prevent", "recruit", "repository", "rho", "sperm cell", "tool" ], "approved": true } }, { "type": "Grant", "id": "7779", "attributes": { "award_id": "3R01EB022230-04S1", "title": "Image-Guided Drug Delivery for Pancreatic Neuroendocrine Tumor", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 22599, "first_name": "TATJANA", "last_name": "Atanasijevic", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-16", "end_date": "2022-09-21", "award_amount": 651080, "principal_investigator": { "id": 23584, "first_name": "Hak Soo SOO", "last_name": "Choi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23585, "first_name": "Maged M", "last_name": "Henary", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "(limit within 30 lines) The COVID-19 emerged in December 2019 and then spread rapidly over 214 countries. As of May 15, 2020, a total of more than 4.5M confirmed cases and over 300,000 deaths have been reported worldwide, posing significant health and economic threats to our society. Currently, an array of drugs approved for other indications have been studied, in addition to multiple investigational agents, for the treatment of COVID-19. Antivirals including remdesivir, favipiravir, chloroquine, and hydroxychloroquine have been rapidly tested in these clinical studies and demonstrated preliminary efficacy against COVID-19. However, these studies also revealed that a proportion of patients receiving remdesivir had significant adverse effects, including multiple-organ dysfunction syndrome, septic shock, and acute liver and kidney injury. Similarly, the use of chloroquine and hydroxychloroquine in COVID-19 patients has raised serious safety concerns including arrhythmias, cardiomyopathy, and retinopathy. These adverse effects are related to their wide distribution of drugs in the whole body after administration, causing damages in off-target vital organs. Therefore, tissue-specific delivery of antiviral therapeutics would ameliorate adverse effects while maintaining their efficacy to treat COVID-19. Our hypothesis that renal clearable ultrasmall nanocarriers can payload antiviral drugs selectively and deliver them to treat COVID-19 with reduced side effects. In our parent R01 (NIBIB #R01EB022230), we have developed ultrasmall nanocarriers for targeting, imaging, and image-guided surgery of pancreatic neuroendocrine tumors. Importantly, over 80% of the unbound dose was ultimately eliminated into the urine within 24 h post-injection after systemic circulation. This narrows the design of nanocarriers to include a targeting anchor, an imaging moiety, and a distribution domain, and we have worked diligently to create a reciprocal arrangement whereby each chemical composition provides balancing properties to the others. Interestingly, during the evaluation of inclusion complexation, we found that the nanocarriers can deliver other types of drugs including imatinib (Kang et al. Adv Mater, 2020). This result suggests that ultrasmall nanocarriers can also deliver antiviral drugs to the target with reduced side effects due to rapid renal clearance of unbound molecules. Therefore, the ultimate goal in this administrative supplement application is to develop ultrasmall nanotherapeutics that are complexed with antivirals to treat COVID-19. By payloading selected antiviral drugs into the ultrasmall nanocarriers, we will be able to achieve image-guided drug delivery to the respiratory system with reduced side effects due to the rapid renal clearance of unbound drugs. To achieve this goal, we propose 1) to develop renal clearable nanocarriers for antiviral drug delivery and 2) to evaluate the pharmacodynamics and therapeutic efficacy of the nanocarriers in mouse models of coronavirus infection. Armed with the near- infrared fluorophores conjugated on the nanocarrier, we will also monitor the biodistribution and clearance of antivirals as well as their targetability and therapeutic efficacy under the real-time imaging system.", "keywords": [ "2019-nCoV", "Acute Renal Failure with Renal Papillary Necrosis", "Administrative Supplement", "Adverse effects", "Affect", "Antineoplastic Agents", "Antiviral Agents", "Arrhythmia", "Biodistribution", "Biological", "Biological Assay", "Blood Circulation", "COVID-19", "Caliber", "Cardiomyopathies", "Cardiotoxicity", "Cells", "Cessation of life", "Chemical Engineering", "Chemicals", "Chloroquine", "Clinical Research", "Complex", "Coronavirus Infections", "Country", "DNA-Directed RNA Polymerase", "Development", "Dose", "Drug Delivery Systems", "Drug Kinetics", "Drug Targeting", "Emerging Communicable Diseases", "Equilibrium", "Evaluation", "Excretory function", "Extinction (Psychology)", "Fluorescence", "Foundations", "Goals", "Grant", "Histology", "Hydroxychloroquine", "Hypotension", "Image", "Image-Guided Surgery", "Imatinib", "Injections", "Injury to Kidney", "Interdisciplinary Study", "Investigation", "Islet Cell Tumor", "Kidney", "Lung", "Measures", "Monitor", "Multiple Organ Failure", "National Institute of Biomedical Imaging and Bioengineering", "Near-infrared optical imaging", "Organ", "Parents", "Patients", "Pharmaceutical Preparations", "Pharmacodynamics", "Plaque Assay", "Plasma", "Property", "Pulmonary Pathology", "Renal clearance function", "Reporting", "Research", "Respiratory System", "Retinal Diseases", "Safety", "Septic Shock", "Serum", "Serum Proteins", "Signal Transduction", "Societies", "Support System", "System", "Testing", "Therapeutic", "Time", "Tissues", "Toxic effect", "Treatment Efficacy", "Urine", "Viral", "Viral Load result", "Virion", "Virus", "Virus Diseases", "Work", "acute liver injury", "anti-viral efficacy", "base", "design", "drug distribution", "fluorophore", "glycosylation", "health economics", "heart rhythm", "image guided", "image guided intervention", "image-guided drug delivery", "imaging system", "improved", "in vivo", "liver injury", "mouse model", "nanocarrier", "nanoparticle", "nanotechnology platform", "nanotherapeutic", "prevent", "quantum", "real-time images", "receptor", "remdesivir", "response", "side effect", "small molecule", "success", "targeted delivery", "targeted imaging", "targeted treatment", "tumor", "uptake", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "6514", "attributes": { "award_id": "3U19AI104317-08S1", "title": "Human epidemiology and response to SARS-CoV-2 (HEROS)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 21839, "first_name": "Michael", "last_name": "Minnicozzi", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-04-22", "end_date": "2021-01-31", "award_amount": 210586, "principal_investigator": { "id": 21840, "first_name": "James E.", "last_name": "Gern", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "(from parent grant) The morbidity and cost to society from childhood viral respiratory illnesses (VRI) is staggering, and allergic respiratory disease is rampant. In the search for prevention for these common and important diseases, perhaps the solutions are on the farm. Preliminary results from the Wisconsin Infant Study Cohort (WISC) demonstrate that children raised on farms have reduced VRI and atopic dermatitis, and distinct innate immune cell maturation trajectories in early life. Furthermore, in our preliminary studies mononuclear cells from Amish newborns (high microbial exposure, low rates of allergy) had a more mature phenotype and enhanced antiviral responses compared to WISC newborns. Collectively, these findings support our central hypothesis: farm- related microbial exposures are associated with increased immune cell maturation, decreased viral respiratory illness severity, and decreased allergic sensitization. To address this hypothesis, we will enlist our currently enrolled 204 WISC participants (93 farm, 111 non-farm), and enroll additional Amish, WISC farm, and WISC non-farm families (50/group). Our study has three aims that employ cutting-edge technologies and leverage our investigative team's extensive experience with farm medicine, birth cohorts, respiratory virology and immune development in children. Aim 1: To characterize how farm-related exposures relate to immune development in early life. We hypothesize that farm-related microbial exposures will prompt increased innate immune cell maturation and function in early life, including enhanced anti-inflammatory mechanisms. In these studies, we will identify farming and microbial effects on immune development of key cells (epithelial cell, plasmacytoid dendritic cell, neutrophil, Tregulatory cells) in the mucosal response to viruses and allergens. Aim 2: To determine how farm exposures affect the burden of VRI and rates of allergic diseases. We hypothesize that farm-exposed infants have reduced VRI burden and reduced sensitization to common environmental allergens. In these studies, we will use viral diagnostics to determine infections and illnesses, and measure specific IgE to aeroallergens. Aim 3: To define group-specific associations between farm-related environmental and lifestyle factors, microbial exposure and colonization (nasopharyngeal and stool), immune development, and clinical outcomes (respiratory illness burden and rates of AD and allergic sensitization). We hypothesize that house dust from farm homes, particularly Amish households, has more diverse environmental microbiota communities, more diverse microbial colonization of the nasopharynx and gut, and improved respiratory health outcomes. In these studies, microbial genomics will be used to identify bacteria and fungi in household dust, nasopharynx, and gut samples, and we will analyze relationships with patterns of immune development, VRI, and allergy. Completion of these studies will lead to development of novel strategies for enhancing immune development in early life to achieve primary prevention of VRI and allergic diseases.", "keywords": [ "2019-nCoV", "Address", "Affect", "Age", "Allergens", "Allergic", "Allergic Disease", "Amish", "Anti-Inflammatory Agents", "Antiviral Response", "Atopic Dermatitis", "Bacteria", "Birth", "Cell Maturation", "Cell physiology", "Cells", "Child", "Childhood", "Clinical", "Cohort Studies", "Communities", "Country", "Dendritic Cells", "Development", "Diagnostic", "Disease", "Enrollment", "Environmental Risk Factor", "Epidemiology", "Epithelial Cells", "Family", "Farming environment", "Feces", "Frequencies", "Home environment", "House Dust", "Household", "Human", "Hypersensitivity", "IgE", "Immune", "Immune system", "Infant", "Infection", "Integration Host Factors", "Life", "Lung diseases", "Measures", "Medicine", "Microbe", "Monitor", "Mononuclear", "Morbidity - disease rate", "Mucous Membrane", "Nasopharynx", "Newborn Infant", "Outcome", "Participant", "Pattern", "Phenotype", "Prevention", "Primary Prevention", "Research", "Rhinovirus", "Sampling", "Severities", "Severity of illness", "Societies", "Technology", "Testing", "Universities", "Viral", "Viral Load result", "Virus", "Wisconsin", "airborne allergen", "burden of illness", "cohort", "cost", "environmental allergen", "experience", "fungus", "improved", "lifestyle factors", "microbial", "microbial colonization", "microbial genomics", "microbiota", "neutrophil", "novel", "novel strategies", "parent grant", "programs", "respiratory", "respiratory health", "respiratory virus", "response", "virology" ], "approved": true } }, { "type": "Grant", "id": "10871", "attributes": { "award_id": "3RF1AG077386-01S1", "title": "Stress, Weathering, and Blood-Based Biomarkers of Alzheimer’s Disease: A Longitudinal Study of Low Income, Aging African Americans", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 9727, "first_name": "Janine M", "last_name": "Simmons", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-06-01", "end_date": "2025-05-31", "award_amount": 434599, "principal_investigator": { "id": 23891, "first_name": "Michelle M", "last_name": "Mielke", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23284, "first_name": "Ronald L", "last_name": "Simons", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 888, "ror": "https://ror.org/00te3t702", "name": "University of Georgia", "address": "", "city": "", "state": "GA", "zip": "", "country": "United States", "approved": true }, "abstract": "(From Parent Grant AG077386) Worldwide, over 50 million people have dementia, with Alzheimer's disease (AD) accounting for as much as 70% of all cases. Recently, the NIA in conjunction with the Alzheimer's Association has proposed a biological definition of AD based on the underlying pathological processes of amyloid (A), phosphorylated tau (T), and neurodegeneration (N). Notably, blood-based biomarkers of AT(N) are now available for use in observational studies and may soon be available for clinical utilization. Unfortunately, African Americans have rarely been included in studies of AD or investigations of the AT(N) framework. This omission is critical given that they are at least twice as likely as whites to develop AD and evidence suggests that the nature of the pathology (mixed versus pure AD) and the pathways to onset may be quite different for African Americans compared to whites. The proposed research will use use the Family and Community Health Study (FACHS), a unique 25-year ongoing study of physical and psychosocial well-being among several hundred African American families, to investigate the extent to which a variety of social and economic stressors, lifestyle and genetic factors, rate of aging, and chronic illness impact trajectories of AT(N) biomarkers. The few extant African American dementia studies use samples with higher income and education than the general African American population. In contrast, the FACHS sample contains a substantial proportion of individuals who have faced the challenges of economic hardship, low education, and discrimination for most of their lives. Our team of investigators from the University of Georgia and the Mayo Clinic will begin by performing assays of AT(N) biomarkers using frozen blood samples drawn in 2008 and 2019, as well as a new round of blood samples to be obtained in 2024. These data will enable us to use growth curves with individually varying time points (age) to estimate developmental trajectories of AT(N) biomarkers. Next, we will investigate the unique contributions of various environmental, lifestyle, and biological/physiological factors in accelerating these AT(N) trajectories. We are especially interested in testing models where biological/physiological markers of health serve to mediate or moderate the effect of lifestyle and environmental circumstances on changes in AT(N) biomarkers. Finally, Covid-19 data is currently being collected from the study sample and will be available for use in the proposed project. Thus, we will be able to examine whether AT(N) biomarkers at waves 5 and 8 increase the chances of contracting Covid-19, as well as if having suffered a severe case of the illness elevates AT(N) markers at wave 9.", "keywords": [ "Acceleration", "Accounting", "African American", "African American population", "Age", "Aging", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s Disease Pathway", "Alzheimer’s disease biomarker", "Amyloid", "Biological", "Biological Assay", "Biological Markers", "Biological Models", "Blood specimen", "COVID-19", "Chronic Disease", "Clinic", "Clinical", "Contracts", "Data", "Dementia", "Development", "Discrimination", "Economics", "Education", "Family", "Family and Community Health Study", "Freezing", "Genetic", "Growth", "Health", "Illness impact", "Income", "Individual", "Investigation", "Life Style", "Longitudinal Studies", "Low income", "Mediating", "Nature", "Nerve Degeneration", "Observational Study", "Pathologic Processes", "Pathology", "Pathway interactions", "Persons", "Physiological", "Research", "Research Personnel", "Sampling", "Sampling Studies", "Stress", "Testing", "Time", "Universities", "Weather", "blood-based biomarker", "interest", "parent grant", "psychosocial wellbeing", "social", "stressor", "tau-1" ], "approved": true } }, { "type": "Grant", "id": "8942", "attributes": { "award_id": "1U01IP001152-01", "title": "IP21-002, New Vaccine Surveillance Network", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-01", "end_date": "2026-08-31", "award_amount": 1402123, "principal_investigator": { "id": 24772, "first_name": "Marian G", "last_name": "Michaels", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24773, "first_name": "John V.", "last_name": "Williams", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "(For Components A, B, and C). Acute gastroenteritis (AGE) and acute respiratory illness (ARI) are leading causes of childhood disease, accounting for a large proportion of hospitalizations, Emergency Department (ED) visits, and outpatient visits annually in the US. These illnesses are caused by diverse pathogens, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza viruses, rhinovirus, enterovirus (EV), coronavirus including SARS-CoV-2, adenovirus, rotavirus, norovirus, astrovirus, and sapovirus. Moreover, some of these viruses are associated with other emerging childhood syndromes, including acute flaccid myelitis (AFM) associated with EV, and multisystem inflammatory syndrome in children (MIS-C) associated with SARS-CoV-2. Thus, viral AGE and ARI are of major public health importance, and result in serious long-term consequences for some children. There are few or no effective antivirals for these viruses and vaccination is the most promising intervention. Our goals are to conduct active, prospective population-based surveillance for AGE and ARI; to define the burden of vaccine-preventable diseases; describe the clinical features, natural history, and population dynamics; and establish vaccine effectiveness (VE) of licensed and impending vaccines and monitor VE over time. The New Vaccine Surveillance Network (NVSN) will facilitate these goals. We propose four Specific Aims: Aim 1: to conduct prospective active surveillance for AGE due to norovirus, rotavirus, and other enteric viruses among children seeking healthcare in ED, inpatient, and outpatient settings. (Component A, Mandatory Component 1; Optional Component B) Aim 2: to conduct prospective active surveillance for ARI due to respiratory viruses in these settings. (Component A, Mandatory Component 1; Optional Component B) Aim 3: to conduct prospective active surveillance for AFM syndrome in these settings. (Component A, Mandatory Component 2) Aim 4: to conduct prospective active surveillance for MIS-C. (Optional Component C) The Pittsburgh site has extensive experience with pediatric clinical research, including as a top enrolling NVSN site in the current NVSN cycle. UPMC Children’s Hospital of Pittsburgh (CHP) has a catchment area of >5.5 million people and admits >95% of hospitalized children in the surrounding county of >1.2 million. Thus, the environment is excellent for population-based research. The experienced investigative team includes experts from pediatric infectious diseases, critical care, rheumatology, and cardiology. The data and samples collected in this project will facilitate the capacity to calculate VE for multiple licensed and pending vaccines. The results of this project will inform best practices for diagnosis and treatment, guide vaccine recommendations, and determine public health interventions to prevent viral illness-related medical visits among children.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1383, "pages": 1397, "count": 13961 } } }